tbuckley/cabot-search huggingface dataset:
Innovations in Mixed Methods Evaluations
Authors: Lawrence A. Palinkas, Sapna J. Mendon, Alison B. Hamilton
Journal: Annual Review of Public Health (2019)

Mixed methods research—i.e., research that draws on both qualitative and quantitative methods in varying configurations—is well suited to address the increasing complexity of public health problems and their solutions. This review focuses specifically on innovations in mixed methods evaluations of intervention, program or policy (i.e., practice) effectiveness, and implementation. The article begins with an overview of the structure, function, and process of different mixed methods designs and then provides illustrations of their use in effectiveness studies, implementation studies, and combined effectiveness–implementation hybrid studies. The article then examines four specific innovations: procedures for transforming (or “quantitizing”) qualitative data, application of rapid assessment and analysis procedures in the context of mixed methods studies, development of measures to assess implementation outcomes, and strategies for conducting both random and purposive sampling, particularly in implementation-focused evaluation research. The article concludes with an assessment of challenges to integrating qualitative and quantitative data in evaluation research.
Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo
Authors: Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Eleni-Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos
Journal: Blood (2018)
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
Authors: Gerwin Huls, Dana A. Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, Arjan A. van de Loosdrecht, Bart J. Biemond, Harm Sinnige, Beata Hodossy, Carlos Graux, Rien van Marwijk Kooy, Okke de Weerdt, Dimitri Breems, Saskia Klein, Jürgen Kuball, Dries Deeren, Wim Terpstra, Marie-Christiane Vekemans, Gert J. Ossenkoppele, Edo Vellenga, Bob Löwenberg
Journal: Blood (2019)
Sputum Antineutrophil Cytoplasmic Antibodies in Serum Antineutrophil Cytoplasmic Antibody–Negative Eosinophilic Granulomatosis with Polyangiitis
Authors: Manali Mukherjee, Sruthi R. Thomas, Katherine Radford, Anna Dvorkin-Gheva, Svetlana Davydchenko, Melanie Kjarsgaard, Sarah Svenningsen, Sarah Almas, Lindsey C. Felix, Jennifer Stearns, Quan-Zhen Li, Nader Khalidi, Paige Lacy, Parameswaran K. Nair
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Eosinophilic granulomatosis with polyangiitis (eGPA) is a small-vessel vasculitis where 40% of patients present with serum antineutrophil cytoplasmic antibodies (ANCAs). We examined the presence and clinical relevance of sputum ANCAs in the serum ANCA- patients with eGPA.ANCA was investigated in matched sputum and blood samples collected from 23 patients with eGPA (n = 10, serum ANCA+), 19 patients with eosinophilic asthma (prednisone dependent), and 13 healthy volunteers. IgG reactivity to common target antigens and cytokine profiles in sputum samples were examined. Pathogenicity of detected sputum ANCA was assessed using in vitro degranulation assays.Most patients with eGPA (17 of 23, 74%) showed significantly increased sputum ANCAs compared with patients with eosinophilic asthma (P = 0.002) and healthy controls (P < 0.0001), irrespective of their serum ANCA status. In addition, 16 of 17 (94%) of sputum ANCA+ patients had clinical manifestations of severe asthma compared with 3 of 6 (50%) in the sputum ANCA- subset (P = 0.04). Microarray analysis of 123 common antigens failed to reveal a specific target for the ANCA IgG. However, immunoprecipitated immunoglobulins from ANCA+ sputum allowed extensive extracellular trap formations from both neutrophils and eosinophils in vitro, indicating pathogenicity of detected IgG autoantibodies. Cytokine analysis showed lung-localized increases in CXCL8 (neutrophil/eosinophil chemotaxis), CCL24 (eosinophil recruitment), and CXCL12 (lymphocyte recruitment) in the sputa from ANCA+ patients (P < 0.01).We report a novel finding of ANCA reactivity in the sputa of patients with eGPA in whom disease severity is driven by respiratory complications. Investigating localized autoimmunity may lead to the discovery of novel pathomechanisms, therapeutic targets, and optimal biomarkers for diagnosing and managing eGPA.
Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma
Authors: Madhav Seshadri, Zhengming Chen, Peter Martin, John P. Leonard, Tsiporah B. Shore, Adrienne A. Phillips, Usama Gergis, Sarah C. Rutherford, John N. Allan, Richard R. Furman, Kristy Richards, Jingmei Hsu, Sebastian A. Mayer, Arcania Garcia, Channy Kong, Giorgio Inghirami, Koen Van Besien, Jia Ruan
Journal: Blood (2018)
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Authors: Katherine E Lindblad, Julie Thompson, Gege Gui, Janet Valdez, Tatyana Worthy, Hanna Tekleab, Tom Hughes, Meghali Goswami, Karolyn Oetjen, Dong-Yun Kim, Laura Dillon, Christin DeStefano, Catherine E. Lai, Christopher S. Hourigan
Journal: Blood (2018)
Statin Toxicity
Authors: Natalie C. Ward, Gerald F. Watts, Robert H. Eckel
Journal: Circulation Research (2019)

There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs frequently prescribed to lower cholesterol. However, in spite of their wide-spread use, discontinuation and nonadherence remains a major gap in both the primary and secondary prevention of atherosclerotic cardiovascular disease. The major reason for statin discontinuation is because of the development of statin-associated muscle symptoms, but a range of other statin-induced side effects also exist. Although the mechanisms behind these side effects have not been fully elucidated, there is an urgent need to identify those at increased risk of developing side effects as well as provide alternative treatment strategies. In this article, we review the mechanisms and clinical importance of statin toxicity and focus on the evaluation and management of statin-associated muscle symptoms.
Abstract 20726: Study on the Effect of Different Exercise Intensity on Cardiac Function of Rats With Acute Myocardial Infarction and Differential Expression of Circulating MiRNAs
Authors: Rongjing Ding, Kun Xia, Dayi Hu
Journal: Circulation (2016)

Objective: To study the effect of different exercise intensity on cardiac function and differential expression of circulating microRNAs (miRNAs) , target genes and gene function in rats with Acute ...
AB0834 Better improvement of asdas were achieved in 841 as patients among 6 months of anti-tnf users compared to non-anti-tnf users: results from a real world prospective cohort managed by smart phone system
Authors: X. Ji, J. Zhu, J. Zhang, F. Huang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic and progressive condition of the spine, which is the most common form of spondyloarthritis (SpA). Although anti-TNF agents are the most effective therapy for AS or SpA, it is recommended as the second-line treatment for individuals who have persistently high disease activity despite treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), intolerance or contraindication to NSAIDs. Changes in ankylosing spondylitis disease activity score (ASDAS) are often measured to reflect outcomes in AS trials. However, anti-TNF does not always maintain long-term remission. There is limited evidence about remission rate of 6 months treatment from real-world AS cohorts. <h3>Objectives</h3> The purpose of this study is to compare the remission rate of AS patients among biologics users or non-biologics users from China Ankylosing Spondylitis/Spondyloarthritis Prospective Imaging Cohort (CASPIC). <h3>Methods</h3> CASPIC is an ongoing prospective cohort established by a smart management system[Smart Management System for Spondyloarthritis (SMSP)]. Clinic visits were scheduled based on visits reminder set by rheumatologists (1~6 months). Anti-TNF users were defined as patients who used biological agents during the follow-up period and the baseline was defined as the start time to use the biological agents. Non-biologics users were served as control groups. ASDAS was calculated to assess disease activity in AS. Generalise additive mixed model and curve fitting were used to show the difference between two groups. <h3>Results</h3> There were 841 AS patients in this cohort, 83.4% were male, with mean (±SD) age 30.8 (±8.8) years, mean time since diagnosis 8.3 (±6.1) years (table 1). Mean duration of anti-TNF treatment was 4.1 (±3.5) months. Significant improvements were observed in ASDAS (table 2). Anti-TNF users had more serious disease activity, and better clinical improvement (figure 1). If the duration of anti-TNF treatment was less than 6 months, relapsed rates were higher than those with longer than 6 months of anti-TNF (figure 1). <h3>Conclusions</h3> Anti-TNF therapy had superior improvement than NSAIDs therapy. Anti-TNF should be used for more than 6 months to achieve better and sustained remission and prevent recurrence. <h3>Disclosure of Interest</h3> None declared
AB0863 Analysis of the frequency of uveitis in spondyloarthritis patients and associations with clinical parameters of the disease
Authors: I.M.S. Vale, M.D.S. Mastella, R.B. Trevisol, M.M. Pereira, M.J. do Carmo, I.A. Pereira
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Acute anterior uveitis is the most common extra-articular manifestation of spondyloarthritis (SpA). The ocular inflammation in SpA is restricted to the uvea, usually unilateral and in some cases may precede the clinical characteristics of SpA. <h3>Objectives</h3> The aim of this study is to analyse if the presence of uveitis is associated with a diferent clinical manifestation, laboratorial, radiological and therapetiuc among spondyloarthritis patients. <h3>Methods</h3> This was an observational retrospective study with 153 patients with spondyloarthritis attended in the period from 1997 to 2017 in Florianopolis, Brazil. It was analysed demografical, laboratorial, clinical and therapeutic data in spondyloarthritis patients with or without uveitis. <h3>Results</h3> 26,8% of the patients with spondyloarthritis presented uveitis. The presence of complications was rare, with cataract occurring in only four patients and glaucoma in two of them. A higher frequency of acute anterior uveitis in males (p=0.06) was observed in patients with a family history (p=0.19) and HLA-B27 positive (p=0.14). Patients with spondyloarthritis and uveitis more frequently used anti-TNF (p=0.04) and presented sacroiliitis on imaging tests (p=0.02). There was no association between uveitis and cardiovascular (p=0.44), cutaneous (p=0.13) or gastrointestinal involvement (p=0.10). <h3>Conclusions</h3> Uveitis in patients with spondylarthritis is common, predominantly in males and more frequently, in HLA-B27 positive patients. Ocular manifestation in spondyloarthritis has a low degree of complication when compared to uveitis from other etiologies. The use of immunobiological agents such as anti-TNF is common in patients with uveitis. <h3>References</h3> [1] Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2013;74(1):65–73 [2] Rosenbaum JT. New developments in uveitis associated with HLA B27. Curr Opin Rheumatol. 2017;29(4):298–303. [3] Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther. 2014;8:67–81. [4] Khan MA, Haroon M, Rosenbaum JT. Acute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye. Curr Rheumatol Rep. 2015;17(9). [5] Cantini F, Nannini C, Cassarà E, Kaloudi O, Niccoli L, Cassara E, et al. Uveitis in Spondyloarthritis: An Overview. J Rheumatol Suppl. 2015;93:27–9. [6] Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34(6):999–1002. <h3>Disclosure of Interest</h3> None declared
AB0299 The incidence rate and the management of early rheumatoid arthritis in a single centre interventional clinic
Authors: R. Ješe, K. Perdan Pirkmajer, A. Ambrožič, N. Gašperšič, A. Hočevar, B. Lestan, S. Markez, M. Pavić Nikolić, M. Plešivčnik Novljan, S. Praprotnik, Ž. Rotar, A. Šipek Dolničar, D. Šuput Skvarča, M. Tomšič
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In patients with rheumatoid arthritis (RA), early diagnosis and adherence to the treat to target recommendations (T2T) limit RA progression and improve patients' quality of life.<sup>1</sup> However, the implementation of T2T has always been a challenge, and real-life data are lacking. Slovenia has 40% less rheumatologists per capita than the European Union average, which makes the implementation of management guidelines even more challenging. <h3>Objectives</h3> To determine the incidence of RA and the proportion of patients with incident RA in whom first rheumatology assessment was done within the recommended time frame. <h3>Methods</h3> We analysed the prospectively collected data of adult patients diagnosed with RA during years 2014 to 2016 at the Rheumatology Department of the University Medical Centre Ljubljana, Slovenia. The department provides rheumatology services to a well-defined region with a population of 704.000 adult residents. Dates were recorded for inflammatory joint symptom onset, referral to rheumatologist, first rheumatologic assessment and initiation of DMARD therapy. The percentage of patients assessed by a rheumatologist and/or treated with a DMARD within 12 weeks of symptom onset and the median times for delay were then calculated. <h3>Results</h3> Between 1 January 2014 and 31 December 2016, 341 incident cases of RA (75% females, median age 61.9 (IQR 52–75.4) years) were identified, resulting in an annual incidence rate of 16/100.000 population (in females: 23.6/100.000; in males 8.3/100.000). Most patients (78.6%) were referred to our early interventional clinic. The median time from symptom onset to consultation was 12.9 (IQR 4.4–26.1) weeks, median time from referral to consultation was 1 (IQR 1–3) day. Median DMARD treatment delay was 16.6 (IQR 8.9–33.3) weeks. Within 12 weeks of symptom onset, 161 (47.2%) new RA patients were examined by a rheumatologist and 123 (36.1%) were started on DMARD therapy. <h3>Conclusions</h3> Our prospective data support the recent reports that uncovered a decrease in RA incidence.<sup>2</sup> Moreover, despite the lack of rheumatologists and the heavily protracted nationwide waiting times for first rheumatologist assessment, our early interventional clinic enables us to recognise and manage substantial percentage of RA patients within the recommended time frame. <h3>References</h3> [1] Monti S, et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open2015;1(Suppl 1):e000057. doi:10.1136/rmdopen-2015-000057 [2] Abhishek, et al. Rheumatoid arthritis is getting less frequent—results of a nationwide population-based cohort study. Rheumatology2017;56:36–744–7. <h3>Disclosure of Interest</h3> None declared
Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials
Authors: Sandra Garcia, Olivia Dorsey, Sandi Pruitt, Saurabh Dahiya, David Gerber, Robert Frank Cornell, Daniel Auclair, Robert H. Collins, Steven Devine, Saad Z. Usmani, Larry Anderson, Shaji K. Kumar, Ankit Kansagra
Journal: Blood (2018)
Peter J B Hubner
Authors: Richard Hubner
Journal: BMJ (2019)

Peter Hubner was born in London in 1942, the third son of a Czech antiques dealer who emigrated to England after the first world war. Peter developed an interest in the sciences during his secondary school years at St Benedict’s School in Ealing and qualified with prizes and a distinction from the Middlesex Hospital Medical School in 1965.

After junior house officer posts in London, Peter completed his first senior house officer post in cardiology at Groby Road Hospital in Leicester with Drs Lawson and Goldberg. He returned to London to complete specialist training in adult and paediatric cardiology, acquiring experience in coronary care, cardiac pacing, and cardiac catheterisation for congenital and adult heart disease. However, a favourable impression had been made by both parties at Groby Road, and …
SP0051 Clinical presentation of autoinflammatory diseases in children and adults: how not to miss these patients
Authors: S. Ozen
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Autoinflammatory diseases are diseases of the innate immune system, characterised by attacks of inflammation. The inflammatory attacks can manifest in a variety of forms; fever, is frequent, the skin and musculoskeletal system is often affected. Acute phase reactants are increased in almost all of the patients. The autoinflammatory diseases can be classified according to their leading manifestations such as: those with periodic fevers (and other various features), those with pyogenic features, those with psoriasis, those with features of interferopathies and those with vasculopathy. With this large range of features these diseases are in the differential of many common diseases. Genetic testing is confirmatory but may not be widely available. The differentiating features of especially the common autoinflammatory diseases will be reviewed. <h3>Disclosure of Interest</h3> S. Ozen Consultant for: Novartis, Speakers bureau: SOBI
AB0684 A review of temporal artery biopsies at a district general hospital
Authors: M.A. Yusuf, M. Al-Zaza, T. Walton
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Giant cell arteritis is the most common vasculitis in the western world in the over 50 population. The morbidity associated with its natural progression and treatment is significant. No single investigation has been identified to accurately confirm or reject its diagnosis, though for some years biopsy of the superficial temporal artery has been carried out to support the diagnostic process. More recently, doppler ultrasound of the artery has gained prominence, though its widespread use is limited. Temporal artery biopsy (TAB) is a significant use of resources, involving a surgeon and their team, as well as a histopathologist. It is an invasive procedure with the risks that this entails. It behoves the referring doctor to ensure that the probability of a positive result is as high as practicable. <h3>Objectives</h3> To determine the factors providing the highest likelihood of a positive TAB result. <h3>Methods</h3> The notes of all patients undergoing a TAB during a 3 year period 2013–2016 were requested from the Medical Records department at a district general hospital. The first 100 of these were reviewed by the authors. Each set of notes was examined for the following: - Demographics (sex, age) - The first department the patient was referred to (Rheumatology/Ophthalmology/Neurology/direct from the General Practitioner to Vascular Surgery) - Period of time from symptom onset to biopsy - Period of time on steroids to biopsy - Initial dose of steroids prescribed - Pre-treatment ESR - Pre-treatment CRP - Presence of symptoms (headache/jaw claudication/polymyalgia rheumatica) - Other causes for a raised ESR - The pre-test probability of a positive TAB result as assessed by the reviewer - TAB result as reported by local histopathologist - Evidence of the biopsy result impacting treatment <h3>Results</h3> Of the 100 TAB's reviewed, 16 yielded positive results (16%). A breakdown of the notes review for these patients is included in the following table: <h3>Conclusions</h3> This study has shown that less than a fifth of TAB's conducted during this period at our district general hospital yielded a positive result. There is scope to improve this yield significantly if we identify candidates for TAB better. There was no positive result for any of the 16 patients less than 58 years of age. The majority had a raised CRP and ESR, though one patient had a CRP of 2. This reflects the need for vigilance before discounting GCA as a diagnosis. One patient had a positive TAB even after 28 days of prednisolone 40 mg daily. The majority (14/16) had their biopsy within 3 weeks of steroid initiation, indicating that a short delay in biopsy does not rule out a positive result. This study will help us develop a local pathway including Ophthalmology, Neurology, Vascular Surgery and Primary Care to improve the yield of positive TAB. This will improve patient experience as well as ensure appropriate use of resources. <h3>Disclosure of Interest</h3> None declared
THU0350 Time dependent association of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus
Authors: E. Morand, R. Kandane-Rathnayake, W. Louthrenoo, S.-F. Luo, Y.-J. Wu, A. Lateef, V. Golder, S. Sockalingam, S. Navarra, L. Zamora, L. Hamijoyo, Y. Katsumata, M. Harigai, M. Chan, S. O’Neill, F. Goldblatt, C.S. Lau, A. Hoi, M. Nikpour
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Lupus nephritis (LN) is a common feature of systemic lupus erythematosus (SLE). While LN is considered a contributor to irreversible organ damage in SLE, the magnitude of impact of active renal disease relative to other contributors to damage accrual is unknown. <h3>Objectives</h3> To determine the time-dependent association of active lupus nephritis (LN) with organ damage accrual in SLE. <h3>Methods</h3> This study was performed on patients from the Asia Pacific Lupus Collaboration (APLC) cohort. SLE Disease Activity Index-2000 (SLEDAI-2k) is collected per-visit and SLICC-ACR Damage Index (SDI) annually. Analysis was restricted to patients with ≥2 SDI scores. Active LN was defined if patients had urinary casts, proteinuria, haematuria or pyuria as indicated in the SLEDAI-2k descriptor. Organ damage accrual was defined as a change of SDI (ΔSDI&gt;0) between baseline and final visit. Glucocorticoid (GC) categories were defined according to cumulative GC exposure at each visit as either no GC (cum.GC=0); low GC (cum.GC ≤median) or high GC (cum.GC &gt;median). Cox regression analyses were performed. <h3>Results</h3> 1735 patients and 5593 visits were included in the analysis. 93% of patients was female with a median ([inter-quartile range (IQR), (range)] age of 40 years.<sup><sup>31, 51 18, 77</sup></sup> Median study observation period was 853 days [621, 1094].<sup><sup>98, 1443</sup></sup> 36% were Chinese; 20% Thai and 10% Caucasian ethnicity. 82% of patients were exposed to glucocorticoids. 40% had active renal disease at least once during the study period, and active renal disease was observed in 22% of visits (n=1238 visits). 41% of patients had organ damage at baseline and 14% accrued organ damage (272 damage accrual episodes in 250 patients). Active renal disease was significantly associated with damage accrual; after adjusting for confounders, patients with active renal disease were 66% more likely to accrue organ damage compared to those without active renal disease (adjusted hazard ratio=1.66 (95% CI: 1.26, 2.19), p-value&lt;0.01 (table 1). High cumulative GC and age were also significantly associated with damage accrual. <h3>Conclusions</h3> Active LN is an independent risk factor for damage accrual in SLE. The concomitant independent association of GC exposure with damage accrual suggests non-GC treatments to reduce active LN are needed to reduce damage burden in SLE. <h3>Disclosure of Interest</h3> None declared